Fuzzy Cognitive Maps for Modelling, Predicting and Interpreting HIV Drug Resistance

2012 ◽  
pp. 31-40 ◽  
Author(s):  
Isel Grau ◽  
Gonzalo Nápoles ◽  
Maikel León ◽  
Ricardo Grau
Keyword(s):  
Drug Resistance ◽  
Cognitive Maps ◽  
Fuzzy Cognitive Maps ◽  
Hiv Drug Resistance

Two-steps learning of Fuzzy Cognitive Maps for prediction and knowledge discovery on the HIV-1 drug resistance

2014 ◽  
Vol 41 (3) ◽  
pp. 821-830 ◽  
Author(s):  
Gonzalo Nápoles ◽  
Isel Grau ◽  
Rafael Bello ◽  
Ricardo Grau
Keyword(s):  
Drug Resistance ◽  
Knowledge Discovery ◽  
Cognitive Maps ◽  
Fuzzy Cognitive Maps ◽  
Hiv 1

FUZZY COGNITIVE MAPS EMBEDDED IN A LOW COST AUTONOMOUS MOBILE ROBOT

2019 ◽  
Author(s):  
Márcio Mendonça ◽  
Guilherme Bender Sartori ◽  
Lucas Botoni de Souza ◽  
Giovanni Bruno Marquini Ribeiro
Keyword(s):  
Mobile Robot ◽  
Low Cost ◽  
Cognitive Maps ◽  
Fuzzy Cognitive Maps ◽  
Autonomous Mobile Robot

Genotypic Methods for HIV Drug Resistance Monitoring: The Opportunities and Challenges Faced by China

2019 ◽  
Vol 17 (4) ◽  
pp. 225-239 ◽  
Author(s):  
Lulu Zuo ◽  
Ke Peng ◽  
Yihong Hu ◽  
Qinggang Xu
Keyword(s):  
Drug Resistance ◽  
Virological Suppression ◽  
Testing Methods ◽  
Hiv Drug Resistance ◽  
Advantages And Disadvantages ◽  
Hiv Epidemic ◽  
Routine Surveillance ◽  
The World ◽  
Global Project ◽  
Hiv 1

AIDS is a globalized infectious disease. In 2014, UNAIDS launched a global project of “90-90-90” to end the HIV epidemic by 2030. The second and third 90 require 90% of HIV-1 infected individuals receiving antiretroviral therapy (ART) and durable virological suppression. However, wide use of ART will greatly increase the emergence and spreading of HIV drug resistance and current HIV drug resistance test (DRT) assays in China are seriously lagging behind, hindering to achieve virological suppression. Therefore, recommending an appropriate HIV DRT method is critical for HIV routine surveillance and prevention in China. In this review, we summarized the current existing HIV drug resistance genotypic testing methods around the world and discussed the advantages and disadvantages of these methods.

HIV Drug Resistance Testing in a Resource Limited Setting with High Viral Diversity: The First Twenty Eight Months Experience

2017 ◽  
Vol 15 (4) ◽  
Author(s):  
Elodie Teclaire Ngo-Malabo ◽  
Paul Alain Ngoupo ◽  
Serge Alain Sadeuh-Mba ◽  
Emmanuel Akongnwi ◽  
Robert Banaï ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Resource Limited Setting ◽  
Resistance Testing ◽  
Viral Diversity ◽  
Hiv Drug Resistance ◽  
Drug Resistance Testing ◽  
Resource Limited ◽  
Limited Setting

scholarly journals HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China

Pathogens ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 264
Author(s):  
Miaomiao Li ◽  
Shujia Liang ◽  
Chao Zhou ◽  
Min Chen ◽  
Shu Liang ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Next Generation Sequencing ◽  
Antiretroviral Therapy ◽  
Detection Threshold ◽  
Next Generation ◽  
Resistance Mutations ◽  
Hiv Drug Resistance ◽  
Drug Resistance Mutations ◽  
Therapy Interruption ◽  
Generation Sequencing

Patients with antiretroviral therapy interruption have a high risk of virological failure when re-initiating antiretroviral therapy (ART), especially those with HIV drug resistance. Next-generation sequencing may provide close scrutiny on their minority drug resistance variant. A cross-sectional study was conducted in patients with ART interruption in five regions in China in 2016. Through Sanger and next-generation sequencing in parallel, HIV drug resistance was genotyped on their plasma samples. Rates of HIV drug resistance were compared by the McNemar tests. In total, 174 patients were included in this study, with a median 12 (interquartile range (IQR), 6–24) months of ART interruption. Most (86.2%) of them had received efavirenz (EFV)/nevirapine (NVP)-based first-line therapy for a median 16 (IQR, 7–26) months before ART interruption. Sixty-one (35.1%) patients had CRF07_BC HIV-1 strains, 58 (33.3%) CRF08_BC and 35 (20.1%) CRF01_AE. Thirty-four (19.5%) of the 174 patients were detected to harbor HIV drug-resistant variants on Sanger sequencing. Thirty-six (20.7%), 37 (21.3%), 42 (24.1%), 79 (45.4%) and 139 (79.9) patients were identified to have HIV drug resistance by next-generation sequencing at 20% (v.s. Sanger, p = 0.317), 10% (v.s. Sanger, p = 0.180), 5% (v.s. Sanger, p = 0.011), 2% (v.s. Sanger, p < 0.001) and 1% (v.s. Sanger, p < 0.001) of detection thresholds, respectively. K65R was the most common minority mutation, of 95.1% (58/61) and 93.1% (54/58) in CRF07_BC and CRF08_BC, respectively, when compared with 5.7% (2/35) in CRF01_AE (p < 0.001). In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies. The prevalence of HIV drug resistance in ART interruption was higher than 15% in the survey. Next-generation sequencing was able to detect more minority drug resistance variants than Sanger. There was a sharp increase in minority drug resistance variants when the detection threshold was below 5%.

Sign in / Sign up

Export Citation Format

Share Document